Opdualag
Chemical Name | nivolumab and relatlimab |
Dosage Form | Injection (intravenous; 240 mg of nivolumab and 80 mg of relatlimab per 20 mL (12 mg and 4 mg per mL)) |
Drug Class | Multiple |
System | Multiple |
Company | Bristol-Myers Squibb |
Approval Year | 2022 |
Indication
- For the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.